Nisa Investment Advisors LLC Purchases 1,995 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Nisa Investment Advisors LLC grew its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 10.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,976 shares of the biopharmaceutical company’s stock after acquiring an additional 1,995 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,878,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Joel Isaacson & Co. LLC increased its position in shares of Regeneron Pharmaceuticals by 0.8% in the first quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after buying an additional 25 shares in the last quarter. Cornerstone Advisors Inc. increased its position in Regeneron Pharmaceuticals by 3.7% during the 1st quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 30 shares in the last quarter. Comprehensive Portfolio Management LLC increased its position in Regeneron Pharmaceuticals by 4.1% during the 1st quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 33 shares in the last quarter. Rehmann Capital Advisory Group increased its position in Regeneron Pharmaceuticals by 31.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 210 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 50 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. increased its position in Regeneron Pharmaceuticals by 10.6% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 606 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 58 shares in the last quarter. 66.97% of the stock is owned by institutional investors and hedge funds.

REGN has been the topic of a number of research analyst reports. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 8th. Canaccord Genuity reissued a “hold” rating and set a $353.00 price target (down from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. Piper Jaffray Companies reissued an “overweight” rating and set a $435.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 7th. Jefferies Financial Group dropped their price objective on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a report on Wednesday, April 17th. Finally, Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price objective on the stock in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $398.25.

Shares of REGN stock opened at $304.86 on Wednesday. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. The firm has a market cap of $33.32 billion, a price-to-earnings ratio of 15.40, a PEG ratio of 1.39 and a beta of 1.15. The stock’s fifty day simple moving average is $305.01. Regeneron Pharmaceuticals Inc has a 1 year low of $287.66 and a 1 year high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.60 by $0.69. The business had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The company’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.45 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals Inc will post 19.22 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Derivative

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.